Your AI-Trained Oncology Knowledge Connection!

Updates in the Treatment of Advanced RCC: Highlights from ASCO GU 2024 : Episode 7

Treating Patients with RCC and Brain, Liver, or Bone Metastases

March 19, 2024

By Elizabeth Plimack, MD
Benjamin L. Maughan, MD, PharmD

Opinion

Video

Panelists discuss systemic therapy approaches for RCC patients presenting with brain, liver, or bone metastases, noting more limited efficacy of IO-IO therapy in brain metastases and tendencies to use IO-TKI therapy for aggressive or rapidly progressing disease.

EP: 1.Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

EP: 2.Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

EP: 3.Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

EP: 4.Frontline Treatment Approaches for Advanced Clear Cell RCC

EP: 5.Treatment Decisions for Favorable Risk RCC

EP: 6.Managing Immune-Related Toxicities with Frontline RCC Therapies

EP: 7.Treating Patients with RCC and Brain, Liver, or Bone Metastases

EP: 8.Frontline Therapy for Patients With Non-Clear Cell RCC

EP: 9.Non-Clear Cell RCC: Key Learnings and Future Research Directions

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.

Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.